News

Dentsply Sirona to Participate in the 7th Annual Evercore ISI HealthCONx Conference

CHARLOTTE, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced…

1 year ago

GLUCOTRACK ANNOUNCES START OF ENROLLMENT FOR HUMAN CLINICAL STUDY OF CONTINUOUS BLOOD GLUCOSE MONITOR

Feasibility study underway for the Company’s novel continuous blood glucose monitor in patients with diabetes, with data expected within 6-8…

1 year ago

PetMeds® Adopts Limited Duration Shareholder Rights Plan

DELRAY BEACH, Fla., Dec. 03, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ:…

1 year ago

Kane Biotech Announces $3,000,000 Private Placement Offering

WINNIPEG, Manitoba, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces…

1 year ago

Achieve Life Sciences to Advance First Vaping Cessation Therapy After Successful End-of-Phase 2 Meeting with FDA

Milestone Reinforces the Potential for Cytisinicline as a First-in-Class Treatment for Vaping CessationSEATTLE and VANCOUVER, British Columbia, Dec. 03, 2024…

1 year ago

SeaStar Medical Activates Sentara Norfolk General Hospital and Provides Enrollment Update in Adult AKI Pivotal Trial

DENVER, Dec. 03, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary…

1 year ago

Lipella Pharmaceuticals Announces Publication in CUREUS on Non-Steroid Treatment of Oral Lichen Planus

Peer-reviewed article highlights potential treatment for OLP with focus on localized drug deliveryPITTSBURGH, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Lipella…

1 year ago

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA) today announced it will investigate the ability of its…

1 year ago

Enlivex Announces Positive Interim Efficacy Data from Allocetra Trial in Patients with Moderate to Severe Knee Osteoarthritis

Nes-Ziona, Israel, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy…

1 year ago